Fundz

vTv Therapeutics Inc.

North Carolina, United States · Biopharma, Biotechnology, Healthcare

vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary d

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Headquarters
North Carolina, United States
Employees
Unknown
Industries
Biopharma, Biotechnology, Healthcare
Status
Public (VTVT)
Website
vtvtherapeutics.com
LinkedIn
Company page

Recent activity at vTv Therapeutics Inc.

  • : SEC 8-K (5.03): On October 1, 2026, vTv Therapeutics Inc. approved the adoption of its Third Amended and Restated By-Laws. This amendment includes new procedures for the nomination of directors, requiring stockholders to provide evidence of compliance with Rule 14a-19 of the Securities Exchange Act at least five business days prior to a meeting. Additionally, it revises the voting standards for stockholder meetings, enhancing the governance framework of the company. This change is significant as it may influence future elections and decision-making processes within the company.
  • : SEC 8-K (8.01): On May 13, 2026, vTv Therapeutics Inc. filed a prospectus supplement to increase the number of Class A common stock shares offered under its at-the-market sales program (ATM Program) to the maximum allowable amount. The filing includes a legal opinion from Dechert LLP concerning the legality of the shares being issued through the ATM Program, which is attached as Exhibit 5.1. This move is strategic for the company to raise additional capital through the expanded share offering, reflecting an active financial strategy as part of their ongoing operations.
  • : SEC 8-K (8.01): On May 13, 2026, vTv Therapeutics Inc. filed a prospectus supplement with the SEC to increase the number of shares of Class A common stock offered under its at-the-market sales program to the maximum amount allowed. This filing includes a legal opinion from Dechert LLP regarding the legality of the shares issued under the program. This expansion allows the company to take full advantage of market conditions for capital raising, which could support its operations and growth strategies moving forward.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Employee benefit plans

vTv Therapeutics Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

About vTv Therapeutics Inc.: questions and answers

What does vTv Therapeutics Inc. do?

vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary d

Where is vTv Therapeutics Inc. headquartered?

vTv Therapeutics Inc. is headquartered in North Carolina, United States.

What is the latest news on vTv Therapeutics Inc.?

On May 13, 2026, SEC 8-K (5.03): On October 1, 2026, vTv Therapeutics Inc. approved the adoption of its Third Amended and Restated By-Laws. This amendment includes new procedures for the nomination of directors, requiring stockholders to provide evidence of compliance with Rule 14a-19 of the Securities Exchange Act

Is vTv Therapeutics Inc. a public company?

Yes. vTv Therapeutics Inc. is publicly traded under the ticker VTVT.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches vTv Therapeutics Inc. across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.